Bausch + Lomb Corporation (NYSE: BLCO): Corporate Profile & Financials
Source: Bausch + Lomb Corporation Form 10-K 2025
Bausch + Lomb Corporation stands as one of the oldest and most recognized global corporate enterprises dedicated entirely to eye health. Operating with the foundational mission of helping people “see better, to live better,” the enterprise protects and enhances sight across every phase of human life—from infancy through advanced age.
- Vision Care: Segment revenue: $2.92 B (57.31%).
- Pharmaceuticals: Segment revenue: $1.28 B (25.18%).
- Surgical: Segment revenue: $894.00 M (17.53%).
📋 Quick Facts / Company Snapshot: Bausch + Lomb Corporation
| Metric / Attribute | Disclosed Detail |
|---|---|
| Official Name | Bausch + Lomb Corporation |
| Stock Exchange Symbol | BLCO |
| Primary Stock Exchanges | New York Stock Exchange (NYSE), Toronto Stock Exchange (TSX) |
| Commission File Number | 001-41380 |
| I.R.S. Employer Identification No. | 98-1613662 |
| Jurisdiction of Incorporation | Canada |
| Governing Corporate Law | Canada Business Corporations Act (CBCA) |
| Principal Executive Offices | 520 Applewood Crescent, Vaughan, Ontario, Canada L4K 4B4 |
| Corporate Contact Telephone | (905) 695-7700 |
| Industry Sector | Eye Health / Healthcare (Vision Care, Ophthalmic Pharmaceuticals, Surgical Systems) |
| Founding Year | 1853 |
| Global Commercial Footprint | Presence in approximately 100 countries |
| Total Global Workforce | Approximately 13,000 employees |
| Total Portfolio Breadth | Comprehensive portfolio of approximately 400 products |
| Parent Controlling Entity | Bausch Health Companies Inc. (BHC) |
| Parent Ownership Proportion | Approximately 88% of issued and outstanding common shares (as of February 11, 2026) |
| Chairman & Chief Executive Officer | Brenton L. Saunders |
| Audit and Risk Committee Chair | Sarah B. Kavanagh |
| Key Operating Subsidiaries | Bausch + Lomb Ireland Limited, Bausch & Lomb Incorporated, Bausch + Lomb Netherlands B.V., Whitecap Biosciences LLC, Elios Vision, Inc., TearLab Corporation (d/b/a Trukera Medical), AcuFocus, Inc. |
| External Corporate Website | www.bausch.com |
1. Corporate Identity: Bausch + Lomb Corporation Overview & History
The Big Picture
Bausch + Lomb Corporation stands as one of the oldest and most recognized global corporate enterprises dedicated entirely to eye health. Operating with the foundational mission of helping people “see better, to live better,” the enterprise protects and enhances sight across every phase of human life—from infancy through advanced age. The company operates a fully integrated commercial, research, development, and manufacturing engine encompassing approximately 400 products marketed directly or indirectly in approximately 100 countries across the globe.
The enterprise spans the entire continuum of ophthalmic medical disciplines. Rather than specializing narrowly in a single sub-field, Bausch + Lomb combines over-the-counter eye care solutions, high-precision contact lens technology, advanced pharmaceutical chemistry for debilitating ocular diseases, and surgical instrumentation used in hospital operating theaters. The global infrastructure supporting this footprint includes an operational workforce of approximately 13,000 individuals worldwide.
- Centuries-Old Operating Heritage: Continuous operations dating back to its establishment in 1853.
- Global Operational Scope: Manufacturing, research, and commercial infrastructure operating across approximately 100 national markets.
- Multidisciplinary Eye Health Coverage: Comprehensive reach across Vision Care, Ophthalmic Pharmaceuticals, and Cataract/Vitreoretinal Surgery.
The Founders & Their Legacy
The historical roots of Bausch + Lomb trace back to 1853 in Rochester, New York, when German immigrant John Jacob Bausch opened a small optical goods shop. Needing additional capital to keep the nascent venture afloat, Bausch borrowed sixty dollars from his friend, Henry Lomb, promising that if the business succeeded, Lomb would become a full partner. The enterprise survived and went on to pioneer the commercial utilization of vulcanite rubber for eyeglass frames, replacing expensive horn and metal frames and making corrective eyewear vastly more durable and affordable for everyday citizens.
Across the subsequent decades, the partnership evolved from a local retail workshop into an industrial optics and precision instruments manufacturer, crafting microscopes, camera lenses, binocular telescopes, and military optical equipment. That legacy of industrial innovation laid the institutional groundwork for modern ophthalmic technology, including breakthrough soft contact lens polymer research in the twentieth century and sophisticated microsurgical systems today.
The Journey: History & Evolution
Bausch + Lomb’s transformation into a modern healthcare titan involved major technological milestones, corporate acquisitions, and structural reorganizations. In 1971, the company achieved an industry breakthrough when it secured regulatory clearance for the world’s first mass-produced soft contact lens, revolutionizing vision correction globally. Over decades, the firm broadened its footprint into eye nutrition, pioneering lens care chemistries, and specialized microsurgical instruments.
In 2013, the business was acquired by Valeant Pharmaceuticals International, Inc. (which later rebranded as Bausch Health Companies Inc., or BHC) in a multi-billion-dollar transaction, integrating the brand into a diversified global pharmaceutical conglomerate. On August 6, 2020, BHC announced a strategic plan to separate Bausch + Lomb into an independent, publicly traded enterprise. In preparation, BHC transferred all relevant entities, assets, liabilities, and operating obligations to Bausch + Lomb Corporation pursuant to a Master Separation Agreement.
The company completed its initial public offering on May 5, 2022, with its common shares debuting for trading on May 6, 2022, on both the New York Stock Exchange and the Toronto Stock Exchange under the ticker symbol “BLCO”. On May 10, 2022, Bausch + Lomb formally separated into an independent publicly traded reporting company, although BHC continues to retain supermajority ownership.
The Corporate Umbrella
Bausch + Lomb Corporation is incorporated under the federal laws of Canada, specifically the Canada Business Corporations Act (CBCA), and maintains its principal corporate executive headquarters in Vaughan, Ontario. As of February 11, 2026, the company’s former sole parent, BHC, directly or indirectly held 310,449,643 common shares, representing approximately 88% of the total issued and outstanding common equity.
Because of this ownership concentration, Bausch + Lomb operates as a “controlled company” under the corporate governance standards of the NYSE and a “majority controlled” company under the rules of the TSX. The ongoing corporate relationship between Bausch + Lomb and BHC is governed by a series of formal separation covenants and operating agreements executed at the time of the IPO:
- Master Separation Agreement (MSA): Establishes the cross-indemnification architecture, liability sharing frameworks, and general terms governing the corporate carve-out.
- Transition Services Agreement (TSA): Provides temporary mutual administrative, technical, human resources, finance, and IT operational support.
- Tax Matters Agreement: Governs tax compliance, shared audits, preservation of tax attributes, and obligations related to the proposed tax-free distribution.
- Employee Matters Agreement: Details the transfer of employee benefits, retirement plan administration, and the treatment of outstanding parent equity awards.
2. The Business Engine: Bausch + Lomb Corporation Business Model & Revenue Segments
The Core Divisions
Bausch + Lomb manages its operations and organizes its commercial activities through three reportable segments: Vision Care, Pharmaceuticals, and Surgical. These divisions reflect how executive leadership allocates capital, measures operating margins, and organizes specialized research and commercial teams.
| Reportable Segment (in $ millions) | 2025 Revenue | 2024 Revenue | 2023 Revenue | 2025 Segment Profit | 2024 Segment Profit | 2023 Segment Profit | Latest YoY (%) |
|---|---|---|---|---|---|---|---|
| Vision Care | 2923 | 2739 | 2543 | 849 | 808 | 689 | +6.72% |
| Pharmaceuticals | 1284 | 1209 | 836 | 258 | 256 | 241 | +6.20% |
| Surgical | 894 | 843 | 767 | 18 | 44 | 50 | +6.05% |
The business performance across divisions highlights distinct operational profiles. Vision Care serves as the high-volume cash generator of the company, generating more than half of consolidated revenues and operating with a 29% segment profit margin in 2025. Within Vision Care, 65% of revenue is derived from consumer eye care products and 35% from contact lenses.
The Pharmaceuticals segment experienced rapid expansion following the acquisition of XIIDRA® in late 2023 and the market rollout of MIEBO®, driving segment top-line growth to $1,284 million. However, net profitability in this division faces heavy gross-to-net rebates and managed-care discounting pressures. The Surgical segment represents the equipment and consumables division, where operating profit contracted sharply in 2025 due to an involuntary product recall of its premium intraocular lens platform.
The Global Product Catalog
The enterprise product catalog encompasses roughly 400 specialized offerings divided across three broad therapeutic channels:
- Vision Care Contact Lenses: A comprehensive spectrum of wearing modalities ranging from daily disposables to frequently replaced soft silicone hydrogel (SiHy) and specialty gas permeable lenses.
- Consumer Eye Care: Leading over-the-counter (OTC) eye drops addressing dry eye disease, redness relief, ocular allergies, and conjunctivitis, accompanied by specialty multi-purpose contact lens cleaning and disinfecting solutions and clinically formulated ocular nutritional supplements.
- Proprietary & Generic Ophthalmic Pharmaceuticals: Prescription eye medications targeting post-operative ocular inflammation, elevated intraocular pressure, glaucoma, dry eye disease, and retinal conditions.
- Surgical Systems & Instruments: State-of-the-art phacoemulsification platforms, femtosecond lasers, intraocular lenses (IOLs) for cataract patients, viscoelastic solutions, vitreoretinal tools, and specialized handheld micro-surgical steel instruments.
The Names You Know
Bausch + Lomb owns and commercializes some of the most recognized consumer healthcare, prescription drug, and medical device brand names in the world:
- PreserVision® AREDS 2: A patented ocular vitamin and mineral supplement based on the landmark National Eye Institute AREDS 2 formula, indicated for people with moderate to advanced age-related macular degeneration (AMD).
- Lumify®: An over-the-counter redness reliever drop (brimonidine tartrate ophthalmic solution, 0.025%) that constricts venules to whiten eyes; expanded in 2025 with a preservative-free line extension.
- Biotrue® & Renu®: Industry-standard multi-purpose lens solutions and eye hydration drops utilizing sodium hyaluronate lubricant matching natural human tears.
- Bausch + Lomb INFUSE® & ULTRA®: High-performance silicone hydrogel contact lenses providing continuous hydration and breathability.
- XIIDRA®: A prescription non-steroid ophthalmic solution acquired from Novartis in 2023, indicated to treat the symptoms and signs of dry eye disease.
- MIEBO®: A novel prescription 100% perfluorohexyloctane water-free eye drop specifically approved to reduce tear evaporation in dry eye disease.
- enVista® & IC-8 Apthera®: Premium intraocular lens platforms inserted into the eye during cataract surgery to restore clear vision and correct corneal astigmatism or presbyopia.
- Stellaris Elite® & VICTUS®: Integrated surgical operating systems combining phacoemulsification, vitrectomy capabilities, and femtosecond laser precision for ophthalmic surgeons.
Mapping the Global Reach
The commercial reach of Bausch + Lomb spans nearly every major international geography. Regional performance reflects customer location across mature healthcare markets and rapidly expanding emerging economies.
| Geographic Market (in $ millions) | 2025 Revenue | 2024 Revenue | 2023 Revenue | Latest YoY (%) |
|---|---|---|---|---|
| U.S. and Puerto Rico | 2546 | 2413 | 1934 | +5.51% |
| China | 358 | 358 | 344 | 0.00% |
| France | 246 | 227 | 210 | +8.37% |
| Japan | 186 | 180 | 187 | +3.33% |
| Germany | 164 | 152 | 147 | +7.89% |
| Russia | 148 | 120 | 106 | +23.33% |
| United Kingdom | 137 | 132 | 121 | +3.79% |
| Canada | 135 | 127 | 110 | +6.30% |
| Italy | 102 | 91 | 82 | +12.09% |
| Spain | 101 | 92 | 85 | +9.78% |
| Mexico | 75 | 75 | 68 | 0.00% |
| Poland | 75 | 65 | 51 | +15.38% |
| South Korea | 51 | 47 | 46 | +8.51% |
| Other Global Regions | 777 | 712 | 655 | +9.13% |
The United States and Puerto Rico represent the company’s single largest market, accounting for approximately half of all consolidated revenues. Commercial execution in the U.S. relies heavily on large pharmaceutical distribution wholesalers, with McKesson Corporation and Cardinal Health, Inc. each generating approximately 10% of Bausch + Lomb’s consolidated net revenue in 2025 and 2024.
International markets contribute the remaining half of revenue, led by substantial commercial operations in China, Western Europe (France, Germany, the UK, Italy, and Spain), and Japan. Even under international sanctions and geopolitical unrest, operations in Russia, Ukraine, and Belarus collectively accounted for approximately 3% of corporate sales in 2025, 2024, and 2023.
The Brick & Mortar Footprint
Bausch + Lomb operates an extensive global network of specialized manufacturing sites, advanced laboratories, distribution centers, and administrative hubs. To optimize collaboration between product design and industrialization, the company frequently co-locates research and development teams alongside manufacturing technicians inside its plants.
| Property Location | Primary Purpose | Segment Supported | Tenure Status | Approximate Square Footage |
|---|---|---|---|---|
| Rochester, New York | Offices, R&D and Manufacturing Facility | Pharmaceuticals + Vision Care | Owned | 953000 |
| Waterford, Ireland | R&D and Manufacturing Facility | Vision Care | Owned | 500000 |
| Woodruff, South Carolina | Distribution Facility | Vision Care | Leased | 432000 |
| Jinan, China | Offices and Manufacturing Facility | Pharmaceuticals + Vision Care | Owned | 418000 |
| Berlin, Germany | R&D, Manufacturing, Distribution and Office Facility | Pharmaceuticals | Owned | 339000 |
| Greenville, South Carolina | Manufacturing Facility | Vision Care | Owned | 314000 |
| Bridgewater, New Jersey | Administration shared with BHC | All Segments | Leased | 310000 |
| Lynchburg, Virginia | Offices and Distribution Facility | Vision Care | Owned | 224000 |
| Aubenas, France | Offices, Manufacturing and Warehouse Facility | Pharmaceuticals | Owned | 193000 |
| Tampa, Florida | R&D and Manufacturing Facility | Pharmaceuticals | Owned | 171000 |
| St. Louis, Missouri | Offices, R&D and Manufacturing Facility | Surgical | Owned | 140000 |
| Macherio, Italy | Offices, Manufacturing and Warehouse Facility | Vision Care | Owned | 119000 |
| Clearwater, Florida | R&D and Manufacturing Facility | Surgical | Owned | 102000 |
| Beijing, China | Manufacturing Facility | Vision Care | Owned | 97000 |
| Eppelheim, Germany | Manufacturing Facility | Surgical | Leased | 78000 |
| Vaughan, Ontario, Canada | Corporate Headquarters and Distribution Facility | All Segments | Leased | 66000 |
The flagship industrial footprint is anchored by the historic 953,000-square-foot complex in Rochester, New York, handling contact lens and lens care manufacturing alongside chemical R&D. Contact lens fabrication is further anchored by the 500,000-square-foot advanced manufacturing center in Waterford, Ireland, while high-volume ophthalmic surgical equipment and intraocular devices are engineered in St. Louis, Missouri, Clearwater, Florida, and Eppelheim, Germany.
3. The Financial Health: Bausch + Lomb Corporation (FY 2025) Audited Financial Statements
Earnings, Expenses & Profits: Bausch + Lomb Corporation Income Statement
Bausch + Lomb’s consolidated financial results demonstrate sustained top-line sales growth driven by product launches and volume gains, countered by high interest burdens and gross-to-net pricing deductions.
| Consolidated Line Item (in $ millions) | 2025 | 2024 | 2023 | Latest YoY (%) |
|---|---|---|---|---|
| Product sales | 5080 | 4774 | 4131 | +6.41% |
| Other revenues | 21 | 17 | 15 | +23.53% |
| Total revenues | 5101 | 4791 | 4146 | +6.47% |
| Cost of goods sold (excluding amortization and impairments of intangible assets) | 2045 | 1868 | 1640 | +9.48% |
| Cost of other revenues | 5 | 4 | 2 | +25.00% |
| Selling, general and administrative | 2234 | 2082 | 1736 | +7.30% |
| Research and development | 371 | 343 | 324 | +8.16% |
| Amortization of intangible assets | 258 | 288 | 240 | -10.42% |
| Other expense, net | 75 | 44 | 74 | +70.45% |
| Operating income | 113 | 162 | 130 | -30.25% |
| Interest income | 12 | 15 | 15 | -20.00% |
| Interest expense | (421) | (399) | (283) | +5.51% |
| Loss on extinguishment of debt | (6) | 0 | 0 | N/M |
| Foreign exchange and other | (15) | (12) | (28) | +25.00% |
| Loss before provision for income taxes | (317) | (234) | (166) | +35.47% |
| Provision for income taxes | (35) | (71) | (82) | -50.70% |
| Net loss | (352) | (305) | (248) | +15.41% |
| Net income attributable to noncontrolling interest | (8) | (12) | (12) | -33.33% |
| Net loss attributable to Bausch + Lomb Corporation | (360) | (317) | (260) | +13.56% |
Consolidated revenue crossed the five-billion-dollar threshold in 2025, reaching $5,101 million. Operating profitability was impacted by multiple operational factors:
- Deduction Escalation: Provisions reducing gross product sales to net sales reached $3,313 million in 2025 (39.5% of gross sales), driven by Managed Care, Medicaid, and co-pay rebates on dry eye medications.
- Manufacturing Headwinds: Cost of goods sold rose to $2,045 million due to higher production volumes, newly enacted U.S. tariffs, and an inventory write-down linked to the enVista IOL voluntary recall.
- Substantial Debt Service: Operating income of $113 million was entirely absorbed by $421 million of net interest expense on senior secured credit facilities and notes, producing a bottom-line net loss attributable to the company of $360 million.
Assets, Debts & Equity: Bausch + Lomb Corporation Balance Sheet
The company maintains a significant asset base composed primarily of operational real estate, capitalized customer and brand intangibles, and goodwill stemming from historical acquisitions.
| Consolidated Balance Sheet Item (in $ millions) | December 31, 2025 | December 31, 2024 | Latest YoY (%) |
|---|---|---|---|
| Cash and cash equivalents | 383 | 305 | +25.57% |
| Restricted cash | 14 | 11 | +27.27% |
| Trade receivables, net | 1221 | 1026 | +19.01% |
| Inventories, net | 976 | 1036 | -5.79% |
| Prepaid expenses and other current assets | 383 | 410 | -6.59% |
| Total current assets | 2977 | 2788 | +6.78% |
| Property, plant and equipment, net | 1762 | 1485 | +18.65% |
| Intangible assets, net | 3281 | 3494 | -6.10% |
| Goodwill | 4758 | 4523 | +5.20% |
| Deferred tax assets, net | 934 | 885 | +5.54% |
| Other non-current assets | 310 | 294 | +5.44% |
| Total assets | 14022 | 13469 | +4.11% |
| Accounts payable | 388 | 389 | -0.26% |
| Accrued and other current liabilities | 1493 | 1309 | +14.06% |
| Current portion of long-term debt and other financial liabilities | 39 | 40 | -2.50% |
| Total current liabilities | 1920 | 1738 | +10.47% |
| Deferred tax liabilities, net | 19 | 13 | +46.15% |
| Other non-current liabilities | 521 | 430 | +21.16% |
| Long-term debt and other financial liabilities | 5043 | 4744 | +6.30% |
| Total liabilities | 7503 | 6925 | +8.35% |
| Common shares, no par value | 0 | 0 | N/M |
| Additional paid-in capital | 8563 | 8429 | +1.59% |
| Accumulated deficit | (931) | (571) | +63.05% |
| Accumulated other comprehensive loss | (1184) | (1385) | -14.51% |
| Total Bausch + Lomb Corporation shareholders’ equity | 6448 | 6473 | -0.39% |
| Noncontrolling interest | 71 | 71 | 0.00% |
| Total equity | 6519 | 6544 | -0.38% |
Intangible assets and goodwill constitute $8,039 million, or over 57% of Bausch + Lomb’s $14,022 million total asset base. Finite-lived product brands ($1,377 million net) and the indefinite-lived B&L Trademark ($1,698 million) represent foundational value drivers. Annual goodwill impairment assessments performed as of October 1, 2025, confirmed that the fair values of all reporting units comfortably exceeded carrying amounts.
Total long-term obligations, inclusive of current portions and failed sale-leaseback financial liabilities, stood at $5,082 million at year-end 2025 ($5,107 million in total contractual debt principal). Total shareholder equity closed the fiscal year at $6,448 million ($6,519 million including noncontrolling interests).
Cash Flow & Capital Allocation: Bausch + Lomb Corporation Cash Flow Statement
Cash flows reflect underlying operating generation offset by continuous capital reinvestment and debt service.
| Consolidated Statement of Cash Flows Item (in $ millions) | 2025 | 2024 | 2023 | Latest YoY (%) |
|---|---|---|---|---|
| Net loss | (352) | (305) | (248) | +15.41% |
| Depreciation and amortization of intangible assets | 421 | 436 | 382 | -3.44% |
| Amortization and write-off of debt premiums, discounts and issuance costs | 18 | 20 | 30 | -10.00% |
| Asset impairments | 0 | 5 | 0 | -100.00% |
| Acquisition-related contingent consideration | (27) | (9) | 2 | +200.00% |
| Allowances for losses on trade receivables and inventories | 31 | 26 | 21 | +19.23% |
| Deferred income taxes | (32) | (10) | (10) | +220.00% |
| Gain on sale of assets | (6) | (5) | 0 | +20.00% |
| Share-based compensation | 149 | 92 | 74 | +61.96% |
| Foreign exchange gain | 2 | 10 | 12 | -80.00% |
| Gain excluded from hedge effectiveness | (10) | (13) | (13) | -23.08% |
| Loss on extinguishment of debt | 6 | 0 | 0 | N/M |
| Amortization of inventory step-up resulting from acquisitions | 62 | 82 | 23 | -24.39% |
| Other non-cash operating adjustments | 3 | (10) | (3) | N/M |
| Change in trade receivables | (148) | (227) | (121) | -34.80% |
| Change in inventories | 38 | (147) | (264) | N/M |
| Change in prepaid expenses and other current assets | 20 | 161 | (147) | -87.58% |
| Change in accounts payable, accrued and other liabilities | 108 | 126 | 245 | -14.29% |
| Net cash provided by (used in) operating activities | 283 | 232 | (17) | +21.98% |
| Acquisitions and other investments | (122) | (138) | (1941) | -11.59% |
| Purchases of property, plant and equipment | (349) | (291) | (181) | +19.93% |
| Purchases of marketable securities | (11) | (12) | (17) | -8.33% |
| Proceeds from sale of marketable securities | 8 | 14 | 16 | -42.86% |
| Proceeds from sale of assets and businesses, net of costs to sell | 7 | 2 | 1 | +250.00% |
| Interest settlements from cross-currency swaps | 12 | 13 | 13 | -7.69% |
| Net cash used in investing activities | (455) | (412) | (2109) | +10.44% |
| Issuance of long-term debt, net of discounts, and other financial liabilities | 3357 | 631 | 2276 | +432.01% |
| Repayments of debt | (3096) | (430) | (161) | +620.00% |
| Payment of employee withholding taxes related to share-based awards | (15) | (12) | (10) | +25.00% |
| Payments of financing costs | (12) | 0 | (16) | N/M |
| Payments of noncontrolling interest distributions | (9) | (10) | (9) | -10.00% |
| Other financing activities | 0 | (1) | (2) | -100.00% |
| Net cash provided by financing activities | 225 | 178 | 2078 | +26.40% |
| Effect of exchange rate changes on cash, cash equivalents and restricted cash | 28 | (16) | 2 | N/M |
| Net increase (decrease) in cash, cash equivalents and restricted cash | 81 | (18) | (46) | N/M |
| Cash, cash equivalents and restricted cash, beginning of period | 316 | 334 | 380 | -5.39% |
| Cash, cash equivalents and restricted cash, end of period | 397 | 316 | 334 | +25.63% |
Operating cash flow expanded to $283 million in 2025, driven by favorable working capital adjustments in inventory management and receivables collections, offsetting higher cash interest costs of $380 million paid across the year.
Investing cash outflows of $455 million were dominated by $349 million in capital expenditures directed toward manufacturing plant modernizations, complemented by $122 million in cash deployed for acquisitions. Financing activities delivered net cash proceeds of $225 million, supported by $3,357 million in debt refinancing drawdowns, including $36 million generated from equipment leaseback agreements.
Funding the Future: R&D and Expansion Spending
Bausch + Lomb sustained high levels of reinvestment across 2025 to safeguard its market standing and accelerate pipeline commercialization:
- Research & Development Expenditure: Scaled to $371 million in 2025, up from $343 million in 2024 and $324 million in 2023, funding clinical development across more than 60 pipeline projects.
- Capital Investments in Physical Infrastructure: Capital expenditures reached $349 million in 2025 (with an additional $51 million of accrued capital purchases), focusing on expanding automated contact lens lines and modernizing pharmaceutical facilities.
- Capitalized Interest: Cumulative capitalized interest on active construction projects reached $112 million as of December 31, 2025, compared to $88 million at year-end 2024.
4. The Corporate Family Tree: Bausch + Lomb Corporation Subsidiaries & Acquisitions
Subsidiaries, Associates, & Shared Ventures
Bausch + Lomb Corporation conducts its international activities through specialized legal entities structured to hold intellectual property, manage local clinical distribution, and operate industrial factories:
- Bausch + Lomb Ireland Limited: A key international operating and intellectual property licensing subsidiary holding vital global commercial product rights, including the dry eye asset XIIDRA® and exclusive licenses for Lumify® and MIEBO®.
- Bausch & Lomb Incorporated: The primary U.S. operating entity handling industrial operations, domestic sales, and joint debt issuance.
- Bausch + Lomb Netherlands B.V.: European holding and financing vehicle that serves as co-issuer of the company’s senior secured notes.
- Whitecap Biosciences LLC: Acquired in January 2025 as an asset acquisition for $28 million upfront to absorb clinical-stage preclinical pipeline therapies in geographic atrophy and glaucoma.
- Elios Vision, Inc.: Wholly owned surgical technology subsidiary acquired in December 2024 for $99 million in cash plus milestone rights, developing excimer laser glaucoma procedures.
- TearLab Corporation (d/b/a Trukera Medical): Acquired in July 2024 to control the ScoutPro® tear osmolarity diagnostic device.
- AcuFocus, Inc.: Medical device subsidiary acquired in January 2023, commercializing the IC-8 Apthera® intraocular lens.
Strategic Investments & Minority Stakes
Bausch + Lomb does not rely on equity-method corporate associates or non-controlled minority joint ventures. Instead, the business pursues external innovation through structured, staged asset acquisitions and licensing agreements with third-party innovators:
- Novaliq GmbH Licensing Partnership: Under a master December 2019 agreement, Bausch + Lomb holds exclusive development and commercialization rights in the U.S. and Canada for MIEBO® (perfluorohexyloctane). As of December 31, 2025, the company had accrued a $35 million milestone obligation payable in early 2026, with an estimated $88 million in future sales-based milestones remaining reasonably possible over time.
- Eye Therapies, LLC Collaboration: Bausch + Lomb licenses the Orange Book-listed patent portfolio protecting Lumify® from Eye Therapies, sharing in Hatch-Waxman enforcement actions.
- Third-Party Manufacturing Asset Deal: On December 9, 2025, the enterprise completed a $75 million asset purchase of specialized manufacturing equipment, assumed a facility lease in Mexico, and entered into milestone commitments of up to $35 million to build in-house surgical capacity.
5. Power & Control: Bausch + Lomb Corporation Executive Leadership & Ownership
The Brain Trust: Board of Directors & Executive Leadership
Governance of Bausch + Lomb is overseen by an experienced healthcare executive leadership team and Board of Directors, with committee oversight structured around independent directors:
- Brenton L. Saunders (Chairman of the Board & Chief Executive Officer): Appointed CEO and Board Chair in February 2023, Saunders oversees global enterprise operations, pipeline development, and strategic execution. He previously served as Chairman and CEO of Allergan and held senior executive roles across the eye health and medical aesthetics industries.
- Sarah B. Kavanagh (Chairperson, Audit and Risk Committee): Independent director providing financial and risk oversight across auditing, financial reporting internal controls, and cybersecurity risk governance.
Who Owns the Stock?
Bausch + Lomb Corporation has unlimited common shares authorized without par value. As of February 11, 2026, there were 354,318,198 common shares issued and outstanding.
The company’s former parent, Bausch Health Companies Inc. (BHC), remains the supermajority controlling shareholder, holding 310,449,643 common shares, or approximately 88% of total outstanding common equity. Non-affiliate public shareholders hold the remaining 12% public float (representing an aggregate market value of $556,990,755 as of June 30, 2025).
BHC has pledged its Bausch + Lomb shares as collateral for certain of its own debt instruments and is actively evaluating methods to complete the corporate separation, whether through a tax-free butterfly reorganization, a return of capital, open market equity secondary sales, or a sale of the company to a third party.
6. Strategic Outlook: Bausch + Lomb Corporation Growth Catalysts & Key Risks
Competitive Advantages & Economic Moats
The long-term economic moat of Bausch + Lomb is anchored in three structural pillars:
- Integrated Cross-Disciplinary Eye Care Scale: Spanning pharmaceuticals, consumer OTC solutions, and microsurgical platforms, the enterprise provides a complete care continuum that competitors specializing in only one field cannot match.
- Formidable Ophthalmic Brand Equity: Brands like PreserVision®, Biotrue®, Lumify®, and Renu® possess extensive consumer trust, leading eye care professional (ECP) recommendations, and high patient loyalty with minimal brand switching.
- High-Barrier Global Manufacturing Network: Operating 16 specialized industrial facilities worldwide compliant with stringent FDA, Health Canada, and European Medicines Agency regulatory standards creates massive entry barriers for prospective competitors.
What Could Go Wrong? Key Challenges & Business Risks
The enterprise faces complex operational, regulatory, and financial risks detailed in its disclosures:
- High Leverage & Floating Interest Rate Exposure: Total debt of $5,082 million includes $3,695 million in variable-rate bank debt. Every upward shift in benchmark SOFR or EURIBOR rates escalates cash interest burdens, which stood at $421 million in 2025.
- Supermajority Parent Overhang: Controlling shareholder BHC holds 88% of common shares. Any forced foreclosure by BHC lenders on pledged collateral, or abrupt secondary equity sales, could cause severe equity price volatility.
- Loss of Exclusivity (LOE) & Generic Encroachment: Key pharmaceutical drivers, including Lumify®, Vyzulta®, and Lotemax® SM, face Hatch-Waxman Paragraph IV patent challenges from generic filers (such as Granules India and Dr. Reddy’s Laboratories). PreserVision® U.S. formulation patents expired in 2021, and method-of-use patents expired in early 2026.
- Product Recalls & Manufacturing Execution: The March 2025 voluntary recall of the enVista IOL line due to toxic anterior segment syndrome (TASS) from vendor raw material variance compressed Surgical segment operating profit by 59% in 2025.
- Geopolitical & Macroeconomic Shocks: Tariffs, counter-tariffs, European healthcare price controls, and ongoing operational risks in Russia and Ukraine (3% of sales) continue to introduce supply and margin friction.
The Next Chapter: Growth & Expansion Initiatives
To overcome loss of patent exclusivity and capture expanding demographic tailwinds from global population aging, Bausch + Lomb is advancing a focused clinical development pipeline comprising over 60 active projects:
- Dry Eye Category Leadership: Expanding commercial adoption of XIIDRA® and MIEBO®, alongside active Phase 2 clinical enrollment for Dual-Action Lifitegrast, designed as the first dual therapeutic addressing both evaporative and inflammatory dry eye.
- Next-Generation Lumify Franchise: Following the 2025 rollout of Lumify® Preservative Free, the company is preparing an NDA submission for “Lumify Luxe” in the first half of 2026.
- PreserVision® AREDS 3: Developing a next-generation eye vitamin formulation targeting moderate-to-advanced age-related macular degeneration, slated to launch in 2026.
- Surgical Glaucoma & Laser Advances: Submitting premarket approval in the U.S. during the first half of 2026 for ELIOS®, the first clinically validated excimer laser minimally invasive glaucoma surgery (MIGS) platform; progressing the SeeNovaTM next-generation microsurgical console and SeeLyraTM femtosecond laser cataract system.
- Contact Lens Material Innovation: Conducting clinical trials on bioactive hyaluronic acid hydrogel daily disposable contact lenses and running multi-year trials for a myopia control lens system.
The Verdict: Strategic Outlook & Conclusion
Bausch + Lomb Corporation possesses an unmatched heritage and a globally diversified commercial infrastructure that generated $5,101 million in revenue across 2025. Its integrated presence across consumer OTC eye health, prescription dry eye therapeutics, and surgical equipment provides defensive cash flow resilience and powerful commercial cross-selling capabilities.
Nonetheless, the company’s financial profile remains temporarily constrained by substantial debt servicing obligations and structural ownership uncertainty stemming from BHC’s 88% controlling equity position. The company’s future value trajectory hinges on its ability to execute scheduled 2026 clinical milestones (including AREDS 3, Lumify Luxe, and the ELIOS® glaucoma platform), expand operating margins via internal manufacturing insourcing, and navigate an orderly, tax-efficient final separation from its parent company.
❓ Frequently Asked Questions: Bausch + Lomb Corporation
What was Bausch + Lomb Corporation’s revenue and net income in FY 2025?
In FY 2025, Bausch + Lomb Corporation reported total revenue of $5.10 B (▲ 6.5% compared to $4.79 B in the prior fiscal year). Gross profit stood at $3.06 B (gross margin of 59.91 %). Operating profit was $113.00 M and bottom-line net income was -$352.00 M.
Is Bausch + Lomb Corporation profitable and generating positive cash flow in FY 2025?
In FY 2025, Bausch + Lomb Corporation reported a net loss of -$352.00 M (PAT margin: -6.90 %). On a cash basis, the company generated $283.00 M in cash flow from operating activities and invested $349.00 M in capital expenditures, resulting in free cash flow of -$66.00 M. Return on Equity (ROE) was -5.40 % and Cash ROE was 4.34 %.
How much debt, assets, and equity does Bausch + Lomb Corporation hold?
As of FY 2025, Bausch + Lomb Corporation held $14.02 B in total assets, $7.50 B in total liabilities, and $6.52 B in total stockholders’ equity. Total debt stood at $5.08 B (debt-to-equity ratio of 0.78x). Net working capital was $1.06 B with a current ratio of 1.55x.
Who is the CEO and CFO of Bausch + Lomb Corporation?
The Chief Executive Officer (CEO) of Bausch + Lomb Corporation is Brenton L. Saunders.
Where is Bausch + Lomb Corporation headquartered and when was it founded?
Bausch + Lomb Corporation is headquartered in 520 Applewood Crescent, Vaughan, Ontario, Canada L4K 4B4. The company traces its founding/incorporation to Canada. Total disclosed workforce/headcount is Approximately 13,000 employees. Its official corporate website is www.bausch.com.
Note: Financial ratios, margins, year-over-year (YoY) growth rates, and percentage shares of revenue are calculated by FirmsWorld based on figures reported in the company’s official SEC filing.